Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2023-190326

Published: 2023

Journal Articles

Radiotherapy As an Effective Bridge for Relapsed/Refractory Secondary CNS Lymphoma

Gustav Cederquist, Kathryn Tringale, Carla Hajj, Harper Hubbeling, Jennifer Ma, Alexandra Dreyfuss, Beatrice Fregonese, Gilles Salles, Christian Grommes, Michael Scordo, Lorenzo Falchi, Joachim Yahalom, Brandon S. Imber

Blood (2023) 142 (Supplement 1): 1759.

https://doi.org/10.1182/blood-2023-190236

Published: 2023

Journal Articles

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Christian Grommes, Han Tun, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Wanying Zhao, Maureen Lane, Catherine Wang, Reinhard von Roemeling, Iris Isufi, Lori A. Leslie, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2023-189746

Published: 2023

Journal Articles

Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma

Christian Grommes, Grzegorz S. Nowakowski, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Meaghan Fowle, Maureen Lane, Catherine Wang, Antonio Omuro, Lori A. Leslie, Carole Soussain, Anna Paulina Dabrowska-Iwanicka, Andrés José María Ferreri, Han Tun

Blood (2023) 142 (Supplement 1): 3143.

https://doi.org/10.1182/blood-2023-190391

Published: 2023

Journal Articles

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Carole Soussain, Samar Issa, Katharine L Lewis, Christian Grommes, Judith Fox, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J Rose, Marcos W Steinberg, Han W. Tun

Blood (2022) 140 (Supplement 1): 12068–12069.

https://doi.org/10.1182/blood-2022-158599

Published: 2022

Journal Articles

Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma

Kathryn R. Tringale, Joachim Yahalom, Michael Scordo, Gustav Y Cederquist, Behroze Vachha, Lauren Schaff, Carla Hajj, Harper Hubbeling, Zhigang Zhang, Charlie White, Christian Grommes, Brandon S. Imber

Blood (2022) 140 (Supplement 1): 1336–1337.

https://doi.org/10.1182/blood-2022-164663

Published: 2022

Journal Articles

Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes

Gustav Y Cederquist, Kathryn R. Tringale, Carla Hajj, Harper Hubbeling, Beatrice Fregonese, Jisun Lee, Michael Scordo, Christian Grommes, Joachim Yahalom, Brandon S. Imber

Blood (2022) 140 (Supplement 1): 6683–6684.

https://doi.org/10.1182/blood-2022-170191

Published: 2022

Journal Articles

Phase Ib/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)

Christian Grommes, Anna Piotrowski, Elena Pentsova, Igor Gavrilovic, Jacqueline B Stone, Andrew Lin, Venissala Wongchai, Juli T Madzsar, Rachna Malani, Craig Nolan, Jasmine Francis, Lisa DeAngelis, Lauren Schaff, Ingo K Mellinghoff

Blood (2022) 140 (Supplement 1): 3807–3808.

https://doi.org/10.1182/blood-2022-157001

Published: 2022

Journal Articles

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Blood (2022) 140 (Supplement 1): 3785–3787.

https://doi.org/10.1182/blood-2022-167915

Published: 2022

Journal Articles

Primary central nervous system lymphoma

Lauren R. Schaff, Christian Grommes

Blood (2022) 140 (9): 971–979.

https://doi.org/10.1182/blood.2020008377

Published: 2022

Journal Articles

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2529.

https://doi.org/10.1182/blood-2021-147527

Published: 2021

Journal Articles

Phase Ib Trial with Dose Expansion of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Patients with Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Christian Grommes, MD, Anna Piotrowski, MD, Elena Pentsova, MD, Craig Nolan, MD, Jasmine Francis, Lisa DeAngelis, MD, Lauren Schaff, MD, Ingo K Mellinghoff, MD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-143075

Published: 2020

Journal Articles

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

Christian Grommes, MD, Igor Gavrilovic, MD, Alexandra M Miller, MD PhD, Jacqueline B Stone, MD, Thomas Kaley, MD, Juli T Madzsar, Alyssa Schumpp, Brittany T Butler, Lauren Schaff, MD, Ingo K Mellinghoff, MD

Blood (2019) 134 (Supplement_1): 1598.

https://doi.org/10.1182/blood-2019-126214

Published: 2019

Journal Articles

Increased Number of High Dose Methotrexate Cycles and the Addition of Rituximab Is Associated with Better Outcomes in a Large Primary CNSL Cohort

Prakirthi Yerram, PharmD, Samantha Nicole Reiss, PharmD, Lisa Modelevsky, PharmD, Lauren Schaff, MD, Anne Reiner, MPH, Katherine Panageas, DrPH, Christian Grommes, MD

Blood (2019) 134 (Supplement_1): 4125.

https://doi.org/10.1182/blood-2019-130349

Published: 2019

Journal Articles

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

Blood (2019) 133 (5): 436–445.

https://doi.org/10.1182/blood-2018-09-875732

Published: 2019

Includes: Supplemental data

Journal Articles

Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)

Christian Grommes, MD, Julia Wolfe, Igor Gavrilovic, MD, Thomas Kaley, MD, Jacqueline Stone, MD, Mariza Daras, MD, Craig Nolan, MD, Elena Pentsova, MD, Vaios Hatzoglou, MD, Ingo Mellinghoff, MD, Lisa DeAngelis, MD

Blood (2018) 132 (Supplement 1): 2965.

https://doi.org/10.1182/blood-2018-99-118538

Published: 2018

Journal Articles

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma

Han W. Tun, Patrick B. Johnston, Lisa M. DeAngelis, Pamela J. Atherton, Levi D. Pederson, Patricia A. Koenig, Craig B. Reeder, Antonio M. Padula Omuro, David Schiff, Brian O’Neill, Jose Pulido, Kurt A. Jaeckle, Christian Grommes, Thomas E. Witzig

Blood (2018) 132 (21): 2240–2248.

https://doi.org/10.1182/blood-2018-02-835496

Published: 2018

Includes: Supplemental data

Journal Articles

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

Christian Grommes, MD, Alessandro Pastore, MD, Igor Gavrilovic, MD, Thomas Kaley, MD, Craig Nolan, MD, Antonio M. Omuro, MD, Julia Wolfe, Elena Pentsova, MD, Vaois Hatzoglou, MD, Ingo Mellinghoff, MD, Lisa DeAngelis, MD

Blood (2016) 128 (22): 783.

https://doi.org/10.1182/blood.V128.22.783.783

Published: 2016

NARROW

CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma

Radiotherapy As an Effective Bridge for Relapsed/Refractory Secondary CNS Lymphoma

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma

Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes

Phase Ib/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Primary central nervous system lymphoma

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

Increased Number of High Dose Methotrexate Cycles and the Addition of Rituximab Is Associated with Better Outcomes in a Large Primary CNSL Cohort

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only